P Vuylsteke1, M Huizing2, K Petrakova3, R Roylance4, R Laing5, S Chan6, F Abell7, S Gendreau8, I Rooney9, D Apt10, J Zhou11, S Singel9, L Fehrenbacher12. 1. Department of Medical Oncology, Université Catholique de Louvain, CHU UCL Namur, Sainte-Elisabeth peter.vuylsteke@cmsenamur.be. 2. Multidisciplinary Breast and Gynaecological Oncology Unit, Universitair Ziekenhuis Antwerpen, Antwerp, Belgium. 3. Department of Medical Oncology, Masaryk Memorial Cancer Institute, Brno, Czech Republic. 4. Department of Medical Oncology, Barts Health NHS Trust and Barts Cancer Institute, Queen Mary University of London, London. 5. Department of Oncology, The Royal Surrey County Hospital, Guildford. 6. Department of Clinical Oncology, Nottingham University Hospitals NHS Trust, Nottingham, UK. 7. Department of Medical Oncology, Calvary Mater Hospital Newcastle, New South Wales, Australia. 8. Oncology Biomarker Development. 9. Product Development Oncology. 10. BioOncology. 11. Product Development Biometrics Biostatistics Department, Genentech Inc., South San Francisco, USA. 12. Kaiser Permanente, Northern California, Vallejo, CA, USA.
Abstract
BACKGROUND: Approximately 40% of hormone receptor-positive, HER2-negative breast cancers (BCs) are associated with activating mutations of the phosphatidylinositol 3-kinase (PI3K) pathway. Pictilisib, a potent and highly specific class I pan-PI3K inhibitor, demonstrated preclinical activity in BC cell lines and may potentiate the effect of taxanes, benefiting patients with or without aberrant activation of the PI3K pathway. PEGGY (NCT01740336), a randomised, placebo-controlled phase II trial, examined whether pictilisib augments the anti-tumour activity of paclitaxel in patients with hormone receptor-positive, HER2-negative locally recurrent or metastatic BC (mBC). We report results from the protocol-specified interim analysis. PATIENTS AND METHODS: One hundred and eighty-three eligible patients were randomised (1:1) to receive paclitaxel (90 mg/m2 weekly for 3 weeks in every 28-day cycle) with either 260 mg pictilisib or placebo (daily on days 1-5 every week). The primary end point was progression-free survival (PFS) in the intention-to-treat (ITT) population and patients with PIK3CA-mutated tumours. Secondary end points included overall response rate (ORR), duration of response, and safety. RESULTS: In the ITT population, the median PFS was 8.2 months with pictilisib (n = 91) versus 7.8 months with placebo (n = 92) [hazard ratio (HR) for progression or death, 0.95; 95% confidence interval (CI) 0.62-1.46; P = 0.83]. In patients with PIK3CA-mutated tumours, the median PFS was 7.3 months for pictilisib (n = 32) versus 5.8 months with placebo (n = 30) (HR, 1.06; 95% CI 0.52-2.12; P = 0.88). ORR was similar between treatment arms. The safety profile of pictilisib was consistent with previous reports, with no new safety signals. Proportions of patients with grade ≥3 adverse events (AEs), serious AEs, and dose reductions/discontinuations due to AEs were higher with pictilisib. CONCLUSIONS: PEGGY did not meet its primary end point, revealing no significant benefit from adding pictilisib to paclitaxel for patients with hormone receptor-positive, HER2-negative locally recurrent or mBC. CLINICAL TRIAL NUMBER: NCT01740336.
RCT Entities:
BACKGROUND: Approximately 40% of hormone receptor-positive, HER2-negative breast cancers (BCs) are associated with activating mutations of the phosphatidylinositol 3-kinase (PI3K) pathway. Pictilisib, a potent and highly specific class I pan-PI3K inhibitor, demonstrated preclinical activity in BC cell lines and may potentiate the effect of taxanes, benefiting patients with or without aberrant activation of the PI3K pathway. PEGGY (NCT01740336), a randomised, placebo-controlled phase II trial, examined whether pictilisib augments the anti-tumour activity of paclitaxel in patients with hormone receptor-positive, HER2-negative locally recurrent or metastatic BC (mBC). We report results from the protocol-specified interim analysis. PATIENTS AND METHODS: One hundred and eighty-three eligible patients were randomised (1:1) to receive paclitaxel (90 mg/m2 weekly for 3 weeks in every 28-day cycle) with either 260 mg pictilisib or placebo (daily on days 1-5 every week). The primary end point was progression-free survival (PFS) in the intention-to-treat (ITT) population and patients with PIK3CA-mutated tumours. Secondary end points included overall response rate (ORR), duration of response, and safety. RESULTS: In the ITT population, the median PFS was 8.2 months with pictilisib (n = 91) versus 7.8 months with placebo (n = 92) [hazard ratio (HR) for progression or death, 0.95; 95% confidence interval (CI) 0.62-1.46; P = 0.83]. In patients with PIK3CA-mutated tumours, the median PFS was 7.3 months for pictilisib (n = 32) versus 5.8 months with placebo (n = 30) (HR, 1.06; 95% CI 0.52-2.12; P = 0.88). ORR was similar between treatment arms. The safety profile of pictilisib was consistent with previous reports, with no new safety signals. Proportions of patients with grade ≥3 adverse events (AEs), serious AEs, and dose reductions/discontinuations due to AEs were higher with pictilisib. CONCLUSIONS: PEGGY did not meet its primary end point, revealing no significant benefit from adding pictilisib to paclitaxel for patients with hormone receptor-positive, HER2-negative locally recurrent or mBC. CLINICAL TRIAL NUMBER: NCT01740336.
Authors: Maura N Dickler; Cristina Saura; Donald A Richards; Ian E Krop; Andrés Cervantes; Philippe L Bedard; Manish R Patel; Lajos Pusztai; Mafalda Oliveira; Alison K Cardenas; Na Cui; Timothy R Wilson; Thomas J Stout; Michael C Wei; Jerry Y Hsu; José Baselga Journal: Clin Cancer Res Date: 2018-05-23 Impact factor: 12.531
Authors: Shu-Xiong Zeng; Yanjun Zhu; Ai-Hong Ma; Weimin Yu; Hongyong Zhang; Tzu-Yin Lin; Wei Shi; Clifford G Tepper; Paul T Henderson; Susan Airhart; Jian-Ming Guo; Chuan-Liang Xu; Ralph W deVere White; Chong-Xian Pan Journal: Clin Cancer Res Date: 2017-08-14 Impact factor: 12.531
Authors: Stephen Leong; Rebecca A Moss; Daniel W Bowles; Joseph A Ware; Jing Zhou; Jill M Spoerke; Mark R Lackner; Geetha Shankar; Jennifer L Schutzman; Ruud van der Noll; Emile E Voest; Jan H M Schellens Journal: Oncologist Date: 2017-08-10
Authors: Neal Shah; Afroz S Mohammad; Pushkar Saralkar; Samuel A Sprowls; Schuyler D Vickers; Devin John; Rachel M Tallman; Brandon P Lucke-Wold; Katherine E Jarrell; Mark Pinti; Richard L Nolan; Paul R Lockman Journal: Pharmacol Res Date: 2018-03-28 Impact factor: 7.658